Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin

Epilepsia

Volumn 37, Issue 3, 1996, Pages 253-257

  Backman, Janne T ^a   Olkkola, Klaus T ^a   Ojala, Mikael ^b   Laaksovirta, Hannu ^b   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Carbamazepine; Drug interaction; Enzyme induction; Midazolam; Phenytoin

Indexed keywords

CARBAMAZEPINE; MIDAZOLAM; MIDAZOLAM MALEATE; PHENYTOIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; EPILEPSY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; CARBAMAZEPINE; DRUG INTERACTIONS; ENZYME INDUCTION; EPILEPSY; FEMALE; FLICKER FUSION; HALF-LIFE; HUMANS; MALE; MIDAZOLAM; MIDDLE AGED; PHENYTOIN; SLEEP;

EID: 0030030330     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1996.tb00021.x     Document Type: Article

References (24)

1. Perucca E, Hedges A, Makki KA, Ruprah M, Wilson JF, Richens A. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984;18:401-10.
2. Perucca E. Pharmacokinetic interactions with antiepileptic drugs. Clin Pharmacokinet 1982;7:57-84.
3. Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin (part I, part II). Clin Pharmacokinet 1990;18:37-60, 131-50.
4. Brodie MJ. Drug interactions in epilepsy. Epilepsia 1992;33: S13-22.
5. Freeman DJ, Laupacis A, Keown PA, Stiller CR, Carruthers SG. Evaluation of cyclosporin-phenytoin interaction with observations of cyclosporin metabolites. Br J Clin Pharmacol 1984;18:887-93.
6. Lele P, Peterson P, Yang S, Jarrell B, Burke JF. Cyclosporin and tegretol - another drug interaction. Kidney Int 1985;27: 344.
7. Pichard L, Fabre I, Fabre G, et al. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Merab Dispos 1990;18:595-606.
8. Dollery C, ed. Therapeutic drugs, vol. 2. Edinburgh: Churchill Livingstone, 1991:M195-9.
9. Allonen H, Ziegler G, Klotz U. Midazolam kinetics. Clin Pharmacol Ther 1981;30:653-61.
10. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989;36:89-96.
11. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994;47:1643-53.
12. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55: 481-5.
13. Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993;53:298-305.
14. Backman JT, Olkkola KT, Aranko K, Himberg J-J, Neuvonen PJ. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994; 37:221-5.
15. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996;59(in press).
16. De Kroon IFI, Langendijk PNJ, De Goede PNFC. Simultaneous determination of midazolam and its three hydroxy metabolites in human plasma by electron-capture gas chromatography without derivatization. J Chromarogr 1989;491: 107-16.
17. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York: Marcel Dekker, 1982.
18. Smith JM, Misiak H. Critical flicker frequency (CFF) and psychotropic drugs in normal human subjects - a review. Psychopharmacology 1976;47:175-82.
19. Hannington-Kiff JG. Measurements of recovery from outpatient general anaesthesia with a simple ocular test. Br Med J 1970;3:132-5.
20. Bond A, Lader MH. The use of visual analogue scales in rating subjective feelings. Br J Med Psychol 1974;47:211-8.
21. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601-7.
22. Mandema JW, Tuk B, van Stevenick AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992;51:715-28.
23. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994;271:557-66.
24. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.